Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Nonbacterial Prostatitis Medication

  • Author: Sunil K Ahuja, MD; Chief Editor: Edward David Kim, MD, FACS  more...
 
Updated: Feb 20, 2016
 

Medication Summary

Medical therapy is important in the treatment of nonbacterial prostatitis to decrease the severity of symptoms and to allow patients to return to normal function. Because nonbacterial prostatitis may originate from infection with a fastidious organism, an empiric trial of antibiotic therapy may provide relief.

Next

Antibiotics

Class Summary

These are often used on a trial basis despite a negative culture result to check for symptom improvement and to rule out infection with a fastidious organism.

Trimethoprim/sulfamethoxazole (Bactrim DS, Septra DS)

 

Trimethoprim blocks dihydrofolate reductase and sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA). These are 2 sequential steps in bacterial biosynthesis of nucleic acids and proteins. This agent is available in single- and double-strength form. In adults, it is most commonly taken in pill form, although a liquid suspension is available.

Levofloxacin (Levaquin)

 

A derivative of pyridine carboxylic acid with a broad-spectrum bactericidal effect, levofloxacin penetrates the prostate well and is effective against Neisseria gonorrhoeae and Chlamydia trachomatis.

Ciprofloxacin (Cipro)

 

Ciprofloxacin is a fluoroquinolone with activity against pseudomonads, streptococci, methicillin-resistant Staphylococcus aureus (MRSA), S epidermidis, and most gram-negative organisms, but no activity against anaerobes. It inhibits bacterial DNA synthesis and, consequently, growth. It diffuses into prostatic fluid and is indicated for chronic prostatitis.

Previous
Next

Alpha-Adrenergic Blocking Agents

Class Summary

Selective alpha-1 receptor blockers relax smooth muscle in the prostate and bladder neck. They have been found to improve symptoms of prostatic obstruction. They are the first choice in therapy for benign prostatic hyperplasia and can be very effective in patients with prostatitis symptoms by improving urine flow and decreasing irritative symptoms.

Doxazosin (Cardura, Cardura XL)

 

Doxazosin inhibits postsynaptic alpha-adrenergic receptors, resulting in vasodilation of veins and arterioles and decrease in total peripheral resistance and blood pressure.

This agent has antihypertensive effects and is recommended to be given at bedtime to prevent patient injury if a syncopal episode occurs. If added to the regimen of antihypertensive medicines a patient is already taking, monitor patient's blood pressure while in titration phase. This agent is usually started as a titration up to the effective dose. It is available in a starter pack containing 1-, 2-, 4-, and 8-mg tablets. The usual effective dose is 4 or 8 mg.

Terazosin

 

Terazosin decreases arterial tone by allowing peripheral postsynaptic blockade. It has minimal alpha-2 effect. As it is an antihypertensive agent, dosing at bedtime is recommended to prevent patient injury if a syncopal episode occurs. If given to a patient already on antihypertensive agents, monitor blood pressure routinely while in titration phase.

Terazosin is usually titrated up to the effective dose. It is available as a starter pack that has doses of 1, 2, 5, and 10 mg.

This agent is sold in capsule form and cannot be broken in half easily; therefore, each specific dose must be prescribed.

Tamsulosin (Flomax)

 

Tamsulosin is an antagonist of the alpha-1a receptor found in smooth muscle of prostate and bladder neck. It is effective for relieving symptoms of prostatic enlargement. Because it is more selective than other alpha-blockers (ie, terazosin and doxazosin), it has minimal, if any, effect on blood pressure and does not require dose titration.

Silodosin (Rapaflo)

 

Silodosin is a selective antagonist of postsynaptic alpha-1-adrenoceptors. It helps relax the smooth muscle in the bladder neck and prostate, causing urine flow and benign prostatic hyperplasia symptoms to improve.

Previous
Next

5-Alpha Reductase Inhibitors

Class Summary

These agents inhibit the conversion of testosterone to dihydrotestosterone (DHT).

Finasteride (Proscar)

 

Finasteride inhibits the steroid 5-alpha-reductase, which converts testosterone into 5-alpha-DHT, causing serum DHT levels to decrease.

Dutasteride (Avodart)

 

Dutasteride is a selective inhibitor of the type 1 and type 2 isoforms of 5-alpha-reductase, which converts testosterone into 5-alpha-DHT, causing serum DHT levels to decrease.

Previous
Next

Nonsteroidal Anti-Inflammatory Agents

Class Summary

These agents inhibit the action of cyclooxygenase, which results in decrease of prostaglandin synthesis.

Ibuprofen (Motrin, Advil, Caldolor)

 

Ibuprofen is the drug of choice for patients with mild to moderate pain. It inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis. It also has anti-inflammatory and antipyretic properties. Ibuprofen is available in 200-, 400-, 600-, and 800-mg doses.

Previous
Next

Benzodiazepines

Class Summary

These agents are indicated for symptomatic relief of pain, burning, urgency, and frequency associated with prostatitis.

Diazepam (Valium, Diastat)

 

Diazepam depresses all levels of the CNS (eg, limbic, reticular formation), possibly by increasing activity of gamma-aminobutyric acid (GABA). It is available as 2-, 5-, and 10-mg doses.

Previous
Next

Interstitial Cystitis Agents

Class Summary

For symptomatic relief of pain, burning, urgency, and frequency associated with prostatitis.

Pentosan polysulfate sodium (Elmiron)

 

A heparinlike derivative of macromolecular carbohydrate that resembles glycosaminoglycans, this agent has anticoagulant and fibrinolytic properties. Its mechanism of action is unknown but it may act to prevent irritative or noxious stimuli in the bladder by inhibiting mucosal cell wall permeability.

Dimethyl sulfoxide (Rimso-50)

 

This agent is converted to dimethyl sulfone and dimethyl sulfide in vivo. It is used intravesically to treat symptoms of interstitial cystitis. When administered intravesically, patients often report a garliclike taste.

Previous
Next

Uricosurics

Class Summary

These agents reduce uric acid levels. They have no analgesic or anti-inflammatory activity.

Allopurinol (Zyloprim, Aloprim)

 

Allopurinol inhibits xanthine oxidase, the enzyme that synthesizes uric acid from hypoxanthine. It reduces synthesis of uric acid without disrupting biosynthesis of vital purines.

Previous
Next

Flower Pollens

Class Summary

Pollen (male flower microspore) enables plant reproduction. Produced in anthers of the flower. May have effects on inflammatory response.

Cernitin pollen extract (Cernilton, Cervital, PollenAid)

 

This product may have anti-inflammatory activity.

Previous
Next

Muscle relaxants

Class Summary

These agents are helpful in relieving discomfort associated with tonically contracted muscles.

Methocarbamol (Robaxin)

 

Methocarbamol reduces nerve impulse transmission from spinal cord to skeletal muscle

Cyclobenzaprine (Flexeril, Amrix, Fexmid)

 

Cyclobenzaprine is a skeletal muscle relaxant that acts centrally and reduces motor activity of tonic somatic origins, influencing both alpha and gamma motor neurons. It is structurally related to tricyclic antidepressants and thus carries some similar liabilities.

Previous
Next

Anticholinergic agents

Class Summary

These agents are used for treatment of overactive bladder to prevent associated symptoms of urinary frequency, urgency, and incontinence.

Tolterodine tartrate (Detrol, Detrol LA)

 

A competitive muscarinic receptor antagonist for overactive bladder, tolterodine differs from other anticholinergic types in that it has selectivity for urinary bladder over salivary glands. It exhibits high specificity for muscarinic receptors and has minimal activity or affinity for other neurotransmitter receptors and other potential targets, such as calcium channels.

Previous
Next

Anticonvulsants, Other

Class Summary

Anticonvulsants used as neuropathic analgesics may be helpful, because myofascial pain may at its core be a spinal-mediated disorder affected by neuropathic dysfunction. Gabapentin has been shown to be effective in treating myofascial and neuropathic pain.

Gabapentin (Neurontin)

 

Gabapentin is a membrane stabilizer. It is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), but, paradoxically, it is thought not to exert an effect on GABA receptors. Gabapentin appears to exert action via the alpha(2)delta1 and alpha(2)delta2 auxiliary subunits of voltage-gaited calcium channels. It is used to manage pain and provide sedation in neuropathic pain.

Titration to effect occurs over several days (300 mg on day 1, 300 mg twice on day 2, and 300 mg 3 times on day 3).

Previous
Next

Tricyclic Antidepressants

Class Summary

Tricyclic antidepressants are commonly used for chronic pain. They help to treat insomnia and reduce painful dysesthesia. These agents treat nociceptive and neuropathic pain syndromes.

Amitriptyline

 

Amitriptyline inhibits the reuptake of serotonin and/or norepinephrine at the presynaptic neuronal membrane, which increases their concentration in the central nervous system (CNS). Amitriptyline may increase or prolong neuronal activity, since the reuptake of these biogenic amines is important physiologically in terminating transmitting activity.

Previous
 
Contributor Information and Disclosures
Author

Sunil K Ahuja, MD Department of Urology, Kaiser Permanente San Jose Medical Center

Sunil K Ahuja, MD is a member of the following medical societies: American Urological Association

Disclosure: Nothing to disclose.

Chief Editor

Edward David Kim, MD, FACS Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Edward David Kim, MD, FACS is a member of the following medical societies: American College of Surgeons, Tennessee Medical Association, Sexual Medicine Society of North America, American Society for Reproductive Medicine, American Society of Andrology, American Urological Association

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Repros.

Acknowledgements

Peter Langenstroer, MD Associate Professor, Department of Urology, Medical College of Wisconsin

Peter Langenstroer, MD is a member of the following medical societies: American Urological Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Krieger JN, Nyberg L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999 Jul 21. 282(3):236-7. [Medline].

  2. Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, Calhoun EA, Pontari MA, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol. 1999 Aug. 162(2):369-75. [Medline].

  3. Sandhu JS. Use of empiric antibiotics in the setting of an increased prostate specific antigen: con. J Urol. 2011 Jul. 186(1):18-9. [Medline].

  4. Loeb S. Use of empiric antibiotics in the setting of an increased prostate specific antigen: pro. J Urol. 2011 Jul. 186(1):17-9. [Medline].

  5. Weidner W. Treating chronic prostatitis: antibiotics no, alpha-blockers maybe. Ann Intern Med. 2004 Oct 19. 141(8):639-40. [Medline].

  6. Forrest JB, Schmidt S. Interstitial cystitis, chronic nonbacterial prostatitis and chronic pelvic pain syndrome in men: a common and frequently identical clinical entity. J Urol. 2004 Dec. 172(6 Pt 2):2561-2. [Medline].

  7. Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol. 1998 Apr. 159(4):1224-8. [Medline].

  8. Nickel JC, Downey J, Hunter D, Clark J. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol. 2001 Mar. 165(3):842-5. [Medline].

  9. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003 Jun. 3(6):359-71. [Medline].

  10. Shoskes DA, Nickel JC, Rackley RR, Pontari MA. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis. 2009. 12(2):177-83. [Medline].

  11. Anderson R, Wise D, Sawyer T, Nathanson BH. Safety and effectiveness of an internal pelvic myofascial trigger point wand for urologic chronic pelvic pain syndrome. Clin J Pain. 2011 Nov-Dec. 27(9):764-8. [Medline].

  12. Barbalias GA, Nikiforidis G, Liatsikos EN. Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol. 1998 Mar. 159(3):883-7. [Medline].

  13. Kaplan SA, Volpe MA, Te AE. A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol. 2004 Jan. 171(1):284-8. [Medline].

  14. Schneider H, Ludwig M, Horstmann A, et al. The efficacy of cernilton in patients with chronic pelvic pain syndrome (CP/CPPS) type NIH III: a randomized prospective, double blind, placebo controlled study. J Urol. 2006. 175(suppl);34:Abstract 105.

  15. Nickel JC, Sorensen R. Transurethral microwave thermotherapy for nonbacterial prostatitis: a randomized double-blind sham controlled study using new prostatitis specific assessment questionnaires. J Urol. 1996 Jun. 155(6):1950-4; discussion 1954-5. [Medline].

  16. Bassotti G, Whitehead WE. Biofeedback, relaxation training, and cognitive behaviour modification as treatments for lower functional gastrointestinal disorders. QJM. 1997 Aug. 90(8):545-50. [Medline].

  17. Kaplan SA, Santarosa RP, D'Alisera PM, Fay BJ, Ikeguchi EF, Hendricks J, et al. Pseudodyssynergia (contraction of the external sphincter during voiding) misdiagnosed as chronic nonbacterial prostatitis and the role of biofeedback as a therapeutic option. J Urol. 1997 Jun. 157(6):2234-7. [Medline].

  18. Chang SC, Hsu CH, Hsu CK, Yang SS, Chang SJ. The efficacy of acupuncture in managing patients with chronic prostatitis/chronic pelvic pain syndrome: A systemic review and meta-analysis. Neurourol Urodyn. 2016 Jan 6. 61(6):1156-9; discussion 1159. [Medline].

  19. Yang ZX, Chen PD, Yu HB, Pi M, Luo WS, Zhuo YY. Study strategies for acupuncture treatment of chronic nonbacterial prostatitis. Zhong Xi Yi Jie He Xue Bao. 2012 Mar. 10(3):293-7. [Medline].

  20. Öztekin İ, Akdere H, Can N, Aktoz T, Arda E, Turan FN. Therapeutic Effects of Oligonol, Acupuncture, and Quantum Light Therapy in Chronic Nonbacterial Prostatitis. Evid Based Complement Alternat Med. 2015. 2015:687196. [Medline].

  21. Anderson RU, Wise D, Sawyer T, Chan C. Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men. J Urol. 2005 Jul. 174(1):155-60. [Medline].

  22. Chen X, Hu C, Peng Y, Lu J, Yang NQ, Chen L, et al. Association of diet and lifestyle with chronic prostatitis/chronic pelvic pain syndrome and pain severity: a case-control study. Prostate Cancer Prostatic Dis. 2016 Mar. 19 (1):92-9. [Medline].

 
Previous
Next
 
Nonbacterial prostatitis. National Institutes of Health Chronic Prostatitis Symptom Index.
Nonbacterial prostatitis. Comparison of new and old prostatitis classifications.
Treatment algorithm for nonbacterial prostatitis.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.